Please enable Javascript
Francine Foss, MD
Articles by Francine Foss, MD
Dr. Foss on Tipifarnib in Relapsed, Refractory, T-Cell Lymphoma
Melissa Badamo
T-Cell Lymphoma
|
September 27, 2024
The farnesyltransferase inhibitor tipifarnib achieved an ORR of 40% and a median duration of response of 3.7 months.
View More